Clinical & Cellular Transplant Immunology
The clinical and cellular transplantation Immunology at Institute of Liver & Biliary Sciences is a state of the art histo-compatibility and immune-genetics testing laboratory that supports busy clinical transplant programs and transplantation research activities.
In ILBS overarching goal of Clinical and Cellular Transplant Immunology unit is to provide the comprehensive diagnostic tests related to liver and kidney transplants as well as for graft rejections.
The human leukocyte antigen (HLA) test, also known as HLA typing or tissue typing, identifies antigens on the white blood cells (WBCs) that determine tissue compatibility for organ transplantation (that is, histo-compatibility testing). Clinical and cellular transplantation Immunology laboratory at ILBS uses DNA-based molecular diagnostic techniques to identify HLA genes at low allele resolution by PCR-SSP (polymerase chain reaction-sequence-specific primers) for kidney and liver transplants. We have state-of-the-art equipments to perform molecular HLA typing. In addition to this laboratory performs investigations for determination of HLA B-27 also. HLA-B27 is strongly associated with a certain set of autoimmune diseases like ulcerative colitis, inflammatory bowel disease and Crohn disease.
Patients with graft rejections may have circulating antibodies that recognize HLA antigens on a donor organ or tissue and experience rapid and irreversible destruction of the graft upon transplantation. Even low levels of antibodies may damage the grafts, so more sensitive antibody tests are used for cross-matching and for identifying the risk of immune antibody-mediated damage. Clinical and cellular transplantation Immunology laboratory at ILBS also provide services for Panel Reactive Antibody (PRA) test to rule out any reaction against pre-existing antibodies.
Clinical and cellular transplantation Immunology laboratory performs complement-dependent cytotoxicty (CDC METHOD) HLA-Cross match Tests and HLA-Cross match by flow cytometry to detect antibodies that react with donor HLA antigens prior to transplantation. The complement-dependent cytotoxic cross-match test detects the presence of allo-antibodies in pre- and post-transplant patients, which may dictate clinical management of transplant patients. Cross-match tests are used primarily for transplant candidates to assess the suitability of a potential donor. In renal transplant, a positive lymphocytotoxic T-cell cross-match is a contraindication for renal transplant, In fact, a positive B-cell cross-match, also carries a high risk of antibody-mediated damage in transplantation and would not be recommended.
Our laboratory also provide services for monitoring of phenotypic characteristics of T-lymphocytes (CD4 and CD8 cells) in peripheral blood, which is commonly performed in the management of human immunodeficiency virus (HIV) positive and chronic hepatitis patients. It also performed to monitoring of organ transplant especially in kidney transplant patients allow us to minimize adverse events of immune-suppression and predict risks of rejection. The serial measurements of CD4 and CD8 lymphocytes to study the influence of immune suppressants are useful for a possible predictive value of lymphocyte count for the occurrence of cancer.
- HLA TYPING
- HLA DNA Typing ABDR
- HLA B-27
- HLA DQ2/DQ8
- TISSUE REJECTION PANEL
- Complement-Dependent Cytotoxicty analysis
- HLA-Cross Match by flow cytometry
- Donor Specific Antibodies ( DSA)
- IMMUNE PHENOTYPING
- Immuno phenotyping for CD4 T cells and CD4/CD8 T cells ratio for HIV monitoring
- Immune deficiencies analyzing the antiviral drug monitoring
- Immune deficiencies of regulatory T cells in autoimmune hepatitis
- Immune Deficiency of NK/NKT cells